Metadatos
Mostrar el registro completo del ítemCompartir este ítem
Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms.
Idioma
EN
Article de revue
Este ítem está publicado en
Cardiovascular Diabetology. 2022-11-15, vol. 21, n° 1, p. 242
Resumen en inglés
Several randomized controlled trials have demonstrated the benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on ischemic stroke in patients with diabetes. In this review, we summarize and discuss the potential ...Leer más >
Several randomized controlled trials have demonstrated the benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on ischemic stroke in patients with diabetes. In this review, we summarize and discuss the potential mechanisms of stroke protection by GLP-1RAs. GLP-1RAs exert multiple anti-atherosclerotic effects contributing to stroke prevention such as enhanced plaque stability, reduced vascular smooth muscle proliferation, increased nitric oxide, and improved endothelial function. GLP-1RAs also lower the risk of stroke by reducing traditional stroke risk factors including hyperglycemia, hypertension, and dyslipidemia. Independently of these peripheral actions, GLP-1RAs show direct cerebral effects in animal stroke models, such as reduction of infarct volume, apoptosis, oxidative stress, neuroinflammation, excitotoxicity, blood-brain barrier permeability, and increased neurogenesis, neuroplasticity, angiogenesis, and brain perfusion. Despite these encouraging findings, further research is still needed to understand more thoroughly the mechanisms by which GLP-1RAs may mediate stroke protection specifically in the human diabetic brain.< Leer menos
Palabras clave en inglés
Animals
Humans
Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Diabetes Mellitus
Type 2
Stroke
Hyperglycemia
Centros de investigación